UroGen Pharma Ltd.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

URGN$25.32-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited; in thousands, except share and per share amounts)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2026	2025	2026	2025
Revenue	$72,456	$24,215	$123,415	$44,469
Cost of revenue	6,572	3,550	10,711	5,880
Gross profit	65,884	20,665	112,704	38,589
Operating expenses:
Research and development expenses	17,336	18,914	32,933	38,785
Selling, general and administrative expenses	48,437	43,199	99,923	78,166
Operating income (loss)	111	(41,448)	(20,152)	(78,362)
Financing on prepaid forward obligation	(4,545)	(4,644)	(9,051)	(9,227)
Interest expense on long-term debt	(4,887)	(4,132)	(9,072)	(8,200)
Interest and other income, net	599	1,299	1,207	3,413
Loss before income taxes	(8,722)	(48,925)	(37,068)	(92,376)
Income tax expense	(5,629)	(1,015)	(857)	(1,407)
Net loss	$(14,351)	$(49,940)	$(37,925)	$(93,783)
Statements of comprehensive loss
Net loss	$(14,351)	$(49,940)	$(37,925)	$(93,783)
Other comprehensive loss
Unrealized loss on investments	(10)	(8)	(21)	(50)
Comprehensive loss	$(14,361)	$(49,948)	$(37,946)	$(93,833)
Net loss per ordinary share - basic and diluted	$(0.28)	$(1.05)	$(0.75)	$(1.97)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share	50,380,112	47,739,816	50,282,221	47,582,610

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.